Holen Sie sich die Stockscreener-App
16.76
2.07%
0.34
Handel nachbörslich:
16.76
Schlusskurs vom Vortag:
$16.42
Offen:
$16.42
24-Stunden-Volumen:
293.43K
Relative Volume:
1.02
Marktkapitalisierung:
$885.03M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-69.13M
KGV:
-13.97
EPS:
-1.2
Netto-Cashflow:
$-50.91M
1W Leistung:
-0.89%
1M Leistung:
-23.96%
6M Leistung:
-6.11%
1J Leistung:
+23.42%
1-Tages-Spanne:
$15.95
$16.85
1-Wochen-Bereich:
$15.28
$17.26
52-Wochen-Spanne:
$10.60
$29.60
Tyra Biosciences Inc Stock (TYRA) Company Profile
Firmenname
Tyra Biosciences Inc
Sektor
Branche
Telefon
(619) 728-4760
Adresse
2656 STATE STREET, CARLSBAD
Tyra Biosciences Inc Stock (TYRA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-06-30 | Eingeleitet | Wedbush | Outperform |
| 2023-02-03 | Eingeleitet | Oppenheimer | Outperform |
| 2022-06-23 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-03-08 | Hochstufung | Jefferies | Hold → Buy |
| 2021-11-08 | Herabstufung | Jefferies | Buy → Hold |
| 2021-10-11 | Eingeleitet | BofA Securities | Buy |
| 2021-10-11 | Eingeleitet | Cowen | Outperform |
| 2021-10-11 | Eingeleitet | Jefferies | Buy |
Alle ansehen
Tyra Biosciences Inc Aktie (TYRA) Neueste Nachrichten
Auour Investments LLC Reduces Position in Tyra Biosciences, Inc. (NASDAQ:TYRA) - MarketBeat
Long Term Trading Analysis for (TYRA) - Stock Traders Daily
Tyra Biosciences (NASDAQ:TYRA) Shares Gap Up Following Insider Buying Activity - MarketBeat
Tyra Biosciences director Nina Kjellson sells $2.28m in stock By Investing.com - Investing.com Australia
Tyra Biosciences director Nina Kjellson sells $2.28m in stock - Investing.com
Tyra Biosciences, Inc. (NASDAQ:TYRA) CFO Purchases $152,000.00 in Stock - MarketBeat
Tyra Biosciences CFO Alan Fuhrman acquires $151,954 in stock - Investing.com
Tyra Biosciences CFO Alan Fuhrman acquires $151,954 in stock By Investing.com - Investing.com UK
Tyra Biosciences (NASDAQ:TYRA) Trading Down 10.2%Here's What Happened - MarketBeat
Tyra Biosciences advances with Phase 2 trial for achondroplasia treatment By Investing.com - Investing.com Australia
Tyra Biosciences advances with Phase 2 trial for achondroplasia treatment - Investing.com
Piper Sandler maintains Overweight on Tyra Biosciences stock By Investing.com - Investing.com Canada
Tyra Biosciences stock target lifted, retains buy on clinical trial data - Investing.com Canada
Tyra Biosciences (NASDAQ:TYRA) Sees Strong Trading Volume on Analyst Upgrade - MarketBeat
FDA clears Tyra Biosciences' trial for dwarfism drug By Investing.com - Investing.com Australia
Tyra Biosciences (NASDAQ:TYRA) Price Target Raised to $32.00 at HC Wainwright - MarketBeat
FDA clears Tyra Biosciences' trial for dwarfism drug - Investing.com India
Tyra Biosciences Receives IND Clearance from FDA to Proceed with Phase 2 Study of TYRA-300 in Pediatric Achondroplasia (BEACH301) - PR Newswire
Tyra Biosciences (NASDAQ:TYRA) Shares Gap DownWhat's Next? - MarketBeat
Tyra Biosciences' (TYRA) "Outperform" Rating Reaffirmed at Wedbush - MarketBeat
Why Is Cancer-Focused Tyra Biosciences Stock Falling On Friday? - Benzinga
Tyra Biosciences Reports Interim Clinical Proof-of-Concept Data for TYRA-300, an Investigational Oral FGFR3-Selective Inhibitor, in Phase 1/2 SURF301 Study in Patients with Metastatic Urothelial Cancer - Marketscreener.com
(TYRA) Long Term Investment Analysis - Stock Traders Daily
Tyra Biosciences Reports Interim Clinical Proof-of-Concept Data for TYRA-300, an Investigational Oral FGFR3-Selective Inhibitor, in Phase 1/2 SURF301 Study in Patients with Metastatic Urothelial Cancer (mUC) - PR Newswire
Tyra Biosciences Reports Interim Clinical Proof-Of-Concept Data for TYRA-300, an Investigational Oral FGFR3-Selective Inhibitor, in Phase 1/2 SURF301 Study in Patients with Metastatic Urothelial Cancer - Marketscreener.com
Wall Street Analysts Think Tyra Biosciences (TYRA) Could Surge 27.88%: Read This Before Placing a Bet - MSN
Tyra Biosciences (NASDAQ:TYRA) Sets New 52-Week HighWhat's Next? - MarketBeat
Tyra Biosciences to Host Conference Call on Interim Clinical Data of TYRA-300 from SURF301 Phase 1/2 Study on October 25, 2024, at 8am ET - Marketscreener.com
Tyra Biosciences stock soars to 52-week high of $28.86 - Investing.com India
Tyra Biosciences stock soars to 52-week high of $28.86 By Investing.com - Investing.com South Africa
RA Capital Management, L.P. Reduces Stake in Tyra Biosciences Inc - Yahoo Finance
Insider Selling: Tyra Biosciences, Inc. (NASDAQ:TYRA) CEO Sells 19,084 Shares of Stock - MarketBeat
Tyra Biosciences (NASDAQ:TYRA) Shares Up 4.2%Here's Why - MarketBeat
Calculating The Intrinsic Value Of Tyra Biosciences, Inc. (NASDAQ:TYRA) - Simply Wall St
Tyra Biosciences: Upcoming FGFR3 Inhibitor Data Is A Major Inflection Point - Seeking Alpha
Here's Why We're Not Too Worried About Tyra Biosciences' (NASDAQ:TYRA) Cash Burn Situation - Yahoo Finance
Tyra Biosciences issues warrants in exchange for common stock - Investing.com India
Tyra Biosciences issues warrants in exchange for common stock By Investing.com - Investing.com UK
Tyra raised to buy by BofA ahead of TYRA-300 data readout (NASDAQ:TYRA) - Seeking Alpha
BofA Upgrades Tyra Biosciences As Investors Focus On Preclinical Data Amid High Benchmarks Set By Johnson & Johnson's Drug - Yahoo Finance
This Datadog Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday - MSN
Tyra Biosciences (NASDAQ:TYRA) Upgraded by Bank of America to Buy - MarketBeat
BofA upgrades Tyra Biosciences shares rating to Buy, raises price target - Investing.com Canada
Tyra Biosciences stock soars to 52-week high of $25.3 By Investing.com - Investing.com Australia
Insider Selling: Tyra Biosciences, Inc. (NASDAQ:TYRA) CEO Sells 10,035 Shares of Stock - MarketBeat
Tyra Biosciences CEO Harris Todd sells $1.5 million in stock By Investing.com - Investing.com South Africa
Tyra Biosciences CEO Harris Todd sells $1.5 million in stock - Investing.com
Tyra Biosciences To Present Initial SURF301 Study Results At The ENA Symposium Next Week - RTTNews
Tyra Biosciences (NASDAQ:TYRA) Hits New 1-Year HighHere's What Happened - MarketBeat
Tyra Biosciences stock soars to 52-week high of $25.3 - Investing.com
Boxer Capital, LLC Increases Stake in Tyra Biosciences Inc - Yahoo Finance
Finanzdaten der Tyra Biosciences Inc-Aktie (TYRA)
Umsatz
Nettogewinn
Free Cashflow
ENV
Tyra Biosciences Inc-Aktie (TYRA) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Kjellson Nina S | Director |
Nov 01 '24 |
Sale |
16.56 |
27,493 |
455,272 |
458,506 |
| Kjellson Nina S | Director |
Oct 30 '24 |
Sale |
16.17 |
11,078 |
179,120 |
472,207 |
| Fuhrman Alan | Chief Financial Officer |
Oct 30 '24 |
Buy |
16.00 |
9,500 |
151,954 |
12,849 |
2.02%
0.47%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Kapitalisierung:
|
Volumen (24h):